1. Additional file 1 of Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
- Author
-
Cano, Amanda, Esteban-de-Antonio, Ester, Bernuz, Mireia, Puerta, Raquel, García-González, Pablo, de Rojas, Itziar, Olivé, Claudia, Pérez-Cordón, Alba, Montrreal, Laura, Núñez-Llaves, Raúl, Sotolongo-Grau, Óscar, Alarcón-Martín, Emilio, Valero, Sergi, Alegret, Montserrat, Martín, Elvira, Martino-Adami, Pamela V., Ettcheto, Miren, Camins, Antonio, Vivas, Assumpta, Gomez-Chiari, Marta, Tejero, Miguel Ángel, Orellana, Adelina, Tárraga, Lluís, Marquié, Marta, Ramírez, Alfredo, Martí, Mercè, Pividori, María Isabel, Boada, Mercè, and Ruíz, Agustín
- Abstract
Additional file 1: Figure S1. Neurology panel of Olink Proteomics (code 95801). Distribution of analytical measuring range, defined by the lower and upper limits of quantification (LLOQ-ULOQ), and normal plasma levels where data is available (dark blue bars) for 92 analytes. Figure S2. Inflammation panel of Olink Proteomics (code 95302). Distribution of analytical measuring range, defined by the limits of quantification LLOQ-ULOQ, for 90 out of 92 analytes. Table S1. List of proteins excluded/included in the study after the quality control analysis. Table S2. Demographics and biochemistry of the BIOFACE cohort. Table S3. Pearson correlations and effect between biomarkers in pEVs and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3. Table S4. Pearson correlations and effect between biomarkers in CSF and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3. Table S5. Pearson correlations and effect between biomarkers in plasma and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3.
- Published
- 2023
- Full Text
- View/download PDF